Announced Thu, 9 Jul · 10:40 IST
No material impact from DRL's Semaglutide supply delay, says OneSource
Business Updates View source PDF
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹1612.00
prior close
₹1642.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+0.8+0.5+0.0+1.2+3.7+2.2+1.5+2.3+4.5————
Up moveDown movePending
AI summary
OneSource Specialty Pharma clarifies that Dr. Reddy's Laboratories' delay in commercial supplies of Semaglutide has no material financial or operational impact on the company. OneSource, which is DRL's manufacturing partner for generic Semaglutide Injection, says it has enough demand from other customers including Canada, with capacities fully committed. It is adding new capacities this quarter and later in the year to meet all demand, including DRL's when ready.
Likely market impact
Reassuring for investors; OneSource says the DRL delay does not affect financials, with alternative demand and capacity ready.